A1 Refereed original research article in a scientific journal
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
Authors: Caimmi D, Baiz N, Tanno LK, Demoly P, Arnavielhe S, Murray R, Bedbrook A, Bergmann KC, De Vries G, Fokkens WJ, Fonseca J, Haahtela T, Keil T, Kuna P, Mullol J, Papadopoulos N, Passalacqua G, Samolinski B, Tomazic PV, Valiulis A, van Eerd M, Wickman M, Annesi-Maesano I, Bousquet J
Publisher: WILEY
Publication year: 2017
Journal: Clinical and Experimental Allergy
Journal name in source: CLINICAL AND EXPERIMENTAL ALLERGY
Journal acronym: CLIN EXP ALLERGY
Volume: 47
Issue: 12
First page : 1526
Last page: 1533
Number of pages: 8
ISSN: 0954-7894
eISSN: 1365-2222
DOI: https://doi.org/10.1111/cea.13025
Background: Visual Analogue Scale (VAS) is a validated tool to assess control in allergic rhinitis patients.Objective: The aim of this study was to validate the use of VAS in the MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) app (Allergy Diary) on smartphones screens to evaluate allergic rhinitis symptoms and disease control.Methods: Each user filled 4 different VAS measuring overall, nasal, ocular, and asthma symptoms at least once. Following COSMIN guidelines, we evaluated internal consistency, (Cronbach's alpha coefficient and test-retest), reliability (intraclass correlation coefficients), sensitivity, and acceptability of the MASK-Rhinitis VAS.Results: Between 1 August 2015 and 31 July 2016, the app was used 14 612 times in 15 countries. A total of 1225 users used it more than once, during the evaluated period. The tool resulted to be statistically satisfactory, showing excellent internal consistency (Cronbach's test > 0.84, test-retest > 0.7), reliability (> 0.9), and acceptability. In addition, the tool had a good sensitivity when users (n = 521) answered the VAS twice in less than 3 hours.Conclusions and Clinical Relevance: The MASK-rhinitis VAS is a reliable and valid tool to assess allergic control on smartphone screens, at the population level.